Journal: Oral Diseases

Article Title: The diagnostic accuracy of saliva testing for SARS‐CoV‐2: A systematic review and meta‐analysis

doi: 10.1111/odi.13934

Figure Lengend Snippet: Sensitivity and specificity of saliva tests for detecting SARS‐CoV‐2. Forest plots of individual/pooled sensitivity and specificity of the included studies (CI: confidence interval; Q: Cochran chi‐square test)

Article Snippet: Assay , One‐Step RT‐ddPCR Advanced Kit for Probes (Bio‐Rad) , TaqPath TM COVID‐19 multiplex real‐time RT‐PCR test (Thermo Fisher Scientific) , SuperScript III Platinium One‐Step real time RT‐PCR kit , SARS‐CoV‐2 RNA dependent RNA polymerase/Helicase (RdRp/Hel) real‐time RT‐PCR , Genesis RT‐PCR SARS‐CoV‐2 (Primer Design) kit , Hologic Aptima SARS‐CoV‐2 TMA assay (Hologic Inc.) real‐time RT‐PCR platform , Allplex 2019‐nCoV Assay (100T) (Seegene Inc) , In house RT‐PCR based on CDC assay.

Techniques:

Journal: Oral Diseases

Article Title: The diagnostic accuracy of saliva testing for SARS‐CoV‐2: A systematic review and meta‐analysis

doi: 10.1111/odi.13934

Figure Lengend Snippet: Diagnostic test accuracy of saliva test for detecting SARS‐CoV‐2 (SROC: summary receiver operating characteristic; SENS: sensitivity; SPEC: specificity; AUC: area under the curve; O: observed data; ♦: Summary Oberating Point; ➖: SORC curve; ‐‐‐: 95% confidence contour; …… 95% prediction contour; 1: Aita et al., ; 2: Altawalah et al., ; 3: Binder et al., ; 4: Chen et al., ; 5: Guclu et al., ; 6: Hanson et al., ; 7: Jamal et al., ; 8: Landry et al., ; 9: Moreno‐Contreras et al., ; 10: Pasomsub et al., ; 11: Procop et al., ; 12: Rao et al., ; 13: Sakanashi et al., ; 14: Senok et al., ; 15: Vaz et al., ; 16: Williams et al., ).

Article Snippet: Assay , One‐Step RT‐ddPCR Advanced Kit for Probes (Bio‐Rad) , TaqPath TM COVID‐19 multiplex real‐time RT‐PCR test (Thermo Fisher Scientific) , SuperScript III Platinium One‐Step real time RT‐PCR kit , SARS‐CoV‐2 RNA dependent RNA polymerase/Helicase (RdRp/Hel) real‐time RT‐PCR , Genesis RT‐PCR SARS‐CoV‐2 (Primer Design) kit , Hologic Aptima SARS‐CoV‐2 TMA assay (Hologic Inc.) real‐time RT‐PCR platform , Allplex 2019‐nCoV Assay (100T) (Seegene Inc) , In house RT‐PCR based on CDC assay.

Techniques: Diagnostic Assay

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center

doi: 10.1093/cid/ciab554

Figure Lengend Snippet: Characteristics of Post-Vaccine Severe Acute Respiratory Syndrome Coronavirus 2 Cases Among Healthcare Personnel

Article Snippet: Initial respiratory SARS-CoV-2 NAAT was conducted on a variety of platforms [ ] including a previously described laboratory-developed reverse-transcription quantitative polymerase chain reaction (RT-qPCR) targeting the envelope gene ( E gene) on the Rotor-Gene Q (Qiagen, Germantown, MD); a laboratory-developed RT-qPCR assay using a PerkinElmer kit targeting the ORF1ab and nucleocapsid gene ([ N gene] PerkinElmer, San Jose, CA); Panther Fusion SARS-CoV-2 (Hologic, Marlborough, MA), a high-throughput RT-qPCR method targeting open reading frame 1ab (ORF1ab); Aptima SARS-CoV-2 (Panther System, Hologic), a transcription mediated amplification method targeting ORF1ab; GeneXpert Xpress SARS-CoV-2 (Cepheid, Sunnyvale, CA), a rapid RT-qPCR method targeting both E and N genes; cobas Liat SARS-CoV-2 & Influenza A/B (Roche, Indianapolis, IN), a point-of-care RT-PCR method targeting ORF1ab and N gene; and e-Plex SARS-CoV-2 (Genmark, Carlsbad, CA), a rapid RT-PCR method targeting the N gene.

Techniques: Mutagenesis

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center

doi: 10.1093/cid/ciab554

Figure Lengend Snippet: Time from vaccination to coronavirus disease 2019 symptom onset and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid amplification test (NAAT). A, Days from first vaccine dose to positive SARS-CoV-2 NAAT (n = 150 PVSCs who tested positive after first vaccine dose prior to receiving second vaccine dose). B, Days from second vaccine dose to positive SARS-CoV-2 NAAT (n = 39 PVSCs who tested positive after second vaccine dose). Abbreviation: PVSC, post-vaccine SARS-CoV-2 cases.

Article Snippet: Initial respiratory SARS-CoV-2 NAAT was conducted on a variety of platforms [ ] including a previously described laboratory-developed reverse-transcription quantitative polymerase chain reaction (RT-qPCR) targeting the envelope gene ( E gene) on the Rotor-Gene Q (Qiagen, Germantown, MD); a laboratory-developed RT-qPCR assay using a PerkinElmer kit targeting the ORF1ab and nucleocapsid gene ([ N gene] PerkinElmer, San Jose, CA); Panther Fusion SARS-CoV-2 (Hologic, Marlborough, MA), a high-throughput RT-qPCR method targeting open reading frame 1ab (ORF1ab); Aptima SARS-CoV-2 (Panther System, Hologic), a transcription mediated amplification method targeting ORF1ab; GeneXpert Xpress SARS-CoV-2 (Cepheid, Sunnyvale, CA), a rapid RT-qPCR method targeting both E and N genes; cobas Liat SARS-CoV-2 & Influenza A/B (Roche, Indianapolis, IN), a point-of-care RT-PCR method targeting ORF1ab and N gene; and e-Plex SARS-CoV-2 (Genmark, Carlsbad, CA), a rapid RT-PCR method targeting the N gene.

Techniques: Amplification